gland pharma glp-1 manufacturing India's Market Heats Up as Mounjaro Leads | CNBC-TV18 posted on the topic FDA restricts non-approved compounded GLP-1

Some patients think they can use this drug for 1 year, it will fix their weight and eating problem, then they can stop it and maintain their lower body weight

Combined activation of GLP-1, GIP, and GCG systems theoretically provides complementary mechanisms: GLP-1-mediated insulin sensitization and satiety promotion, GIP-mediated enhancement of insulin secretion and adipose lipid buffering, and glucagon-mediated direct hepatic lipid oxidation and energy expenditure augmentation

Food and Drug Administration (FDA) as a way to reduce the risk of major adverse cardiovascular events in patients who are overweight or obese and present with cardiovascular disease (CVD)

The evidence is there